Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps.

IF 17.5 1区 医学 Q1 ONCOLOGY
Blanca Navarro Rodrigo, Yaquelin Ortiz Miranda, Jesús Corria-Osorio, George Coukos, Alexandre Harari
{"title":"Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps.","authors":"Blanca Navarro Rodrigo, Yaquelin Ortiz Miranda, Jesús Corria-Osorio, George Coukos, Alexandre Harari","doi":"10.1016/j.trecan.2025.08.002","DOIUrl":null,"url":null,"abstract":"<p><p>Tumor-infiltrating lymphocyte (TIL) therapy has emerged as a transformative approach in cancer immunotherapy, particularly following the recent US Food and Drug Administration (FDA) approval of lifileucel for advanced melanoma. This review synthesizes current insights into the immune correlates and mechanisms underlying the efficacy of TIL therapy, highlighting the pivotal role of tumor immunogenicity, TIL functional states, and the tumor microenvironment (TME). Recent advances in single-cell profiling and biomarker discovery have enabled more precise patient selection and therapy optimization, while novel expansion protocols and engineered TILs are addressing resistance and broadening applicability to non-melanoma tumors. Collectively, these developments underscore the promise of next-generation TIL therapies to revolutionize treatment paradigms across a wider spectrum of solid cancers.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":17.5000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2025.08.002","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tumor-infiltrating lymphocyte (TIL) therapy has emerged as a transformative approach in cancer immunotherapy, particularly following the recent US Food and Drug Administration (FDA) approval of lifileucel for advanced melanoma. This review synthesizes current insights into the immune correlates and mechanisms underlying the efficacy of TIL therapy, highlighting the pivotal role of tumor immunogenicity, TIL functional states, and the tumor microenvironment (TME). Recent advances in single-cell profiling and biomarker discovery have enabled more precise patient selection and therapy optimization, while novel expansion protocols and engineered TILs are addressing resistance and broadening applicability to non-melanoma tumors. Collectively, these developments underscore the promise of next-generation TIL therapies to revolutionize treatment paradigms across a wider spectrum of solid cancers.

TIL治疗疗效的免疫相关因素和机制:目前的见解和知识差距。
肿瘤浸润淋巴细胞(TIL)治疗已成为癌症免疫治疗的一种变革性方法,特别是在最近美国食品和药物管理局(FDA)批准lifileucel治疗晚期黑色素瘤之后。这篇综述综合了目前对TIL治疗疗效的免疫相关因素和机制的见解,强调了肿瘤免疫原性、TIL功能状态和肿瘤微环境(TME)的关键作用。单细胞分析和生物标志物发现的最新进展使得更精确的患者选择和治疗优化成为可能,而新的扩展方案和工程化til正在解决耐药性问题,并扩大对非黑色素瘤肿瘤的适用性。总的来说,这些发展强调了下一代TIL疗法在更广泛的实体癌范围内彻底改变治疗范式的希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Trends in cancer
Trends in cancer Medicine-Oncology
CiteScore
28.50
自引率
0.50%
发文量
138
期刊介绍: Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信